Evidence map›Paper›PMID 26066674›Full record

ArticleThe Journal of clinical endocrinology and metabolism2015

Serum N(1)-Methylnicotinamide Is Associated With Obesity and Diabetes in Chinese.

Ming Liu, Lihua Li, Jihong Chu, Boyu Zhu, Qingtao Zhang, Xueyan Yin, Weimin Jiang, Guoliang Dai, Wenzheng Ju, Zhenxing Wang and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. The role of NADnpj metabolic health and disease · 2025
    Review
  6. Review
  7. Frontiers in cellular neuroscience · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. iScience · 2023
    Article
  17. Association of NADFrontiers in endocrinology · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Ming LiuDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Lihua LiDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Jihong ChuDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Boyu ZhuDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Qingtao ZhangDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Xueyan YinDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Weimin JiangDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Guoliang DaiDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Wenzheng JuDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Zhenxing WangDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Qin YangDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Zhuyuan FangDepartment of Cardiology (M.L., W.J., Z.W., Z.F.), Department of Clinical Pharmacology (J.C., G.D., W.J.), and Department of Endocrinology (B.Z.), Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu, China; Department of Medicine, Physiology and Biophysics, Center for Diabetes Research and Treatment, Center for Epigenetics and Metabolism (M.L., Q.Y.), University of California Irvine, Irvine, California 92697; and Department of Internal Medicine (L.L., Q.Z., X.Y.), Dali University School of Clinical Medicine, Dali 671003, Yunnan, China.
Dali University · CNUniversity of California, Irvine · USNanjing University · CN

Funding

Nicotinamide N-methyltransferase is a novel regulator of energy expenditureR01DK100385 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI YANG, QIN · 2014 to 2018
$1.7M
NIDDK NIH HHS R01 DK100385
6 · The paper itself

Abstract

contextNicotinamide N-methyltransferase (NNMT) is a novel histone methylation modulator that regulates energy metabolism, and NNMT knockdown prevents diet-induced obesity in mice. However, whether NNMT plays a role in human obesity and type 2 diabetes (T2DM) remains to be elucidated.

objectiveNNMT catalyzes methylation of nicotinamide to generate N(1)-methylnicotinamide (me-NAM). We aimed to investigate the associations of serum me-NAM with obesity and T2DM in Chinese. DESIGN, SETTING, AND

participantsThe study subjects (n = 1160) were recruited from Dali, a city of Yunnan Province, in southwest China. Anthropometric phenotypes, fasting glucose, and serum lipids were measured. Serum me-NAM was measured by liquid chromatography-mass spectrometry.

resultsSerum me-NAM was positively correlated with body mass index and waist circumference and negatively with high-density lipoprotein (P ≤ .03). The correlations remained highly significant in the multivariate adjusted correlation analyses. In men (n = 691), positive correlations between me-NAM and fasting glucose, low-density lipoprotein, liver function, and serum creatinine levels were also observed in both simple and multivariate adjusted correlation analyses. In multiple logistic regression analyses, elevated serum me-NAM was associated with higher risks for overweight/obesity (odds ratios, 2.36 and 5.78; 95% confidence intervals, 1.10-5.08 and 1.78-18.76 for men and women, respectively; P ≤ .03) and diabetes (odds ratios, 1.56 and 1.86; 95% confidence intervals, 1.10-2.22 and 1.05-3.31 for men and women, respectively; P ≤ .03).

conclusionsThis first large-scale population study shows that me-NAM, as an indicator of NNMT activity, is strongly associated with obesity and diabetes, supporting NNMT as a potential target for treating obesity and diabetes in humans.

Indexed as

AdultAsian PeopleBody Mass IndexChinaCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedNiacinamideObesityOverweightN(1)-methylnicotinamideNiacinamide

Identifiers

PMID26066674
PMCPMC4525009
OpenAlexW1912012159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.